The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Methylation profiles of AP and BP MPN may predict responses to hypomethylating agents
Raajit Rampal, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the association between methylation profile and response to decitabine-based therapy for patients with accelerated (AP) and blast phase (BP) myeloproliferative neoplasms (MPNs). Analysis of samples available from the MPD-RC 109 study (NCT02076191), which tested the safety and efficacy of ruxolitinib in combination with decitabine, demonstrated that the methylation profile of MPN-AP/BP may predict response to hypomethylating agent-based therapies, such as decitabine. IDH2-mutant MPN-AP/BP was found to be epigenetically distinct. Further validation of these observations is required. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
